- Title
- Potential roles of Helicobacter pylori treatment, body mass index and waist circumference in the causation of erosive esophagitis: a randomized clinical trial (HEROES-GERD)
- Creator
- Mazzoleni, Felipe; Mazzoleni, Luiz Edmundo; Breyer, Helenice Pankowski; Spinato Torresini, Ronaldo; Ott, Andre; Wortmann, Andre Castagna; de Lucena Theil, Alexandro; Stifft, Jonathas; Zenker, Raquel Petrucci; Krumel, Candice Franke; Michalczuk, Matheus Truccolo; De Araujo, Alexandre; de Magalhães Francesconi, Carlos Fernando; Canevese, AP; Volpato, N; da Silva, CA; Schaefer, PG; Titton, NF; Longo, L; Edelweiss, MI; Simon, D; Talley, Nicholas Joseph; Sander, Guilherme Becker; Von Reisswitz, Pamela Schitz; Milbradt, Tobias Cancian; da Veiga Chaves Picon, Rafael; Uchoa, Diego Mendonca; De Bona, Laura Renata; Andreolla, Huandeer Felipe
- Relation
- International Journal of Obesity Vol. 44, Issue 1, p. 147-158
- Publisher Link
- http://dx.doi.org/10.1038/s41366-019-0391-3
- Publisher
- Nature Publishing Group
- Resource Type
- journal article
- Date
- 2020
- Description
- Background: In recent decades, the prevalence of gastroesophageal reflux disease (GERD) and obesity has been increasing while Helicobacter pylori infection has been decreasing. Objective: To evaluate if H. pylori treatment, excess body weight and other anthropometric measurements are associated with incident erosive esophagitis, as a secondary objective of a trial which tested the efficacy of treatment of H. pylori on the symptoms of functional dyspepsia. Subjects/methods: Upper gastrointestinal endoscopy and anthropometric assessments were performed, at baseline and after 12 months, in H. pylori positive patients with functional dyspepsia who had no baseline reflux symptoms or esophagitis. Patients were randomly assigned to receive omeprazole, amoxicillin, and clarithromycin (antibiotic group; n = 201) or omeprazole plus placebo (control group; n = 203). The primary outcome was the incidence of esophagitis 12 months after randomization, according to treatment groups, and the association of BMI and other anthropometric measurements. Results: Four hundred and four patients were included (mean age, 46.1 years; 78.7% women). The 12-month follow-up endoscopic esophagitis rates for the antibiotic and control groups were 10.9% (22/201) and 9.4% (19/203), respectively (p = 0.60). The number needed to harm was 67. Baseline anthropometric measurements were performed in 94% (380/404) of patients. The 12-month follow-up esophagitis rates for overweight and normal body weight patients were 13.6% (29/213) and 6.0% (10/167), respectively (p = 0.015); rates for patients with and without increased baseline waist circumference were 15.4% (24/156) and 6.7% (15/224), respectively (p = 0.006). Following logistic regression, only the combination of increased baseline body mass index and waist, but not H. pylori treatment, was independently associated with new-onset esophagitis (OR 2.88; 95% CI: 1.28–6.45). Conclusions: Excess body weight and concomitant increased waist circumference, but not H. pylori treatment, predicts new-onset esophagitis.
- Subject
- bacteria; obesity; adult; body mass index; SDG 3; Sustainable Development Goals
- Identifier
- http://hdl.handle.net/1959.13/1443382
- Identifier
- uon:41979
- Identifier
- ISSN:0307-0565
- Language
- eng
- Reviewed
- Hits: 9357
- Visitors: 9339
- Downloads: 0